hotspot -WSS

hotspot

author：entertainment 2025-09-28 15:55:14 - browse：97

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： New company forms to vet health AI models, root out weaknesses

explore

WSS

New report analyzes digital physical therapy solutions' effectiveness

Health care court cases: Humana, Sutter, Novant

Report captures long Covid’s disabling effects and policy challenges

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cigna wins case to block Amy Bricker's move to CVS

Does Medicare's free annual wellness visit do any good?

hotspot

hotspot

explore

Apple is now the first public company to be valued at $3 trillion

Eat, drink, but be wary — 4 foods that interact with medications

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Moonlake's readout produced a cash windfall. Risks remain

Lifetime voting ban for felony convictions struck down in Mississippi

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

NIH tests clinical research in primary care with $30 million program

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How faith leaders like me can help address America's obesity epidemic

explore

Parkland mass shooting to be reenacted for lawsuit

'Essentially witchcraft:' A former naturopath takes on the field

Scientists find bacteria from stomach of ancient iceman

Moderna says combo Covid

How faith leaders like me can help address America's obesity epidemic

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

explore

hotspot

focus

focus